Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder - 01/09/11
Doi : 10.1067/mjd.2002.126273
Abstract |
Rituximab, a chimeric monoclonal antibody directed against CD20 of B cells, has been reported to be effective in the treatment of B-cell lymphomas and malignant and nonmalignant plasma cell-dependent diseases. We describe a 30-year-old woman with refractory pemphigus vulgaris who experienced a partial remission after treatment with rituximab. (J Am Acad Dermatol 2002;47:785-8.)
Le texte complet de cet article est disponible en PDF.Plan
 | Conflict of interest: None identified. |
| Dr Tredget is an Alberta Heritage Senior Scholar and receives research support from the Canadian Institutes of Health Research. |
 | Reprints not available from authors. |
© 2002
American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 47 - N° 5
P. 785-788 - novembre 2002 Retour au numéro
Article précédent
- Pemphigoid gestationis with predominant involvement of oral mucous membranes and IgA autoantibodies targeting the C-terminus of BP180
- Iakov Shimanovich, Christian Skrobek, Christian Rose, Zhuxiang Nie, Takashi Hashimoto, Eva-Bettina Bröcker, Detlef Zillikens
- Topical tacrolimus for repigmentation of vitiligo
- Pearl E. Grimes, Teresa Soriano, Marlene T. Dytoc
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?